Alpha7 nAChR Allosteric Modulators for Cognitive Impairment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, such as L-DOPA treatment for Parkinson's, have limitations including side effects like dyskinesia and inadequate modulation of α7 nAChR, which are not effectively addressed by existing treatments.
Innovation Solution
Development of novel compounds that act as positive allosteric modulators of the α7 nAChR, which can be used alone or in combination with other therapeutic agents to modulate α7 nAChR activity, thereby addressing cognitive impairments and potentially reducing the severity of L-DOPA-induced dyskinesia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If L-DOPA is used to treat Parkinson's disease, then motor symptoms are improved, but dyskinesia side effects occur
Solution Approach 1:
The patent uses α7 nAChR as an intermediary target to modulate dopaminergic transmission indirectly. By activating α7 nAChR with positive allosteric modulators, the treatment achieves motor symptom control while reducing L-DOPA-induced dyskinesia, as the α7 nAChR acts as a mediator between acetylcholine and dopamine systems in the basal ganglia
Solution Approach 2:
The patent changes the therapeutic parameter from direct dopaminergic stimulation (L-DOPA) to allosteric modulation of α7 nAChR. This parameter change allows for fine-tuned control of receptor activity, increasing endogenous acetylcholine signaling efficacy without the harmful overstimulation effects of L-DOPA
2Reliability
If α7 nAChR agonists are used to improve cognition, then cognitive function is enhanced, but selectivity over related channel targets is reduced
Solution Approach 1:
The patent applies local quality by designing positive allosteric modulators that bind to a specific allosteric site on the α7 nAChR subunit. This localized binding approach provides selective modulation of α7 nAChR function without affecting other nicotinic acetylcholine receptor subtypes, achieving cognitive improvement with high target selectivity
Solution Approach 2:
The positive allosteric modulator acts as an intermediary that enhances endogenous acetylcholine signaling at α7 nAChR without directly activating the receptor. This indirect mechanism provides selective cognitive enhancement while avoiding off-target effects associated with direct agonists
3Reliability
If acetylcholinesterase inhibitors are used to increase cholinergic transmission, then cognitive symptoms are improved, but side effects increase
Solution Approach 1:
The patent changes the mechanism from non-selective acetylcholinesterase inhibition to selective α7 nAChR allosteric modulation. This parameter change provides cognitive symptom management with improved side effect profile by specifically enhancing α7 nAChR function rather than broadly increasing acetylcholine levels
Data Source
AI summary
The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.